Immunotherapy Market

The global immunotherapy market was valued at USD 124.4 billion in 2025 and is estimated at USD 142.0 billion in 2026. Revenue is projected to reach USD 410.9 billion by 2034, reflecting a 14.2% CAGR during 2026–2034.

The immunotherapy market covers medicines and therapeutic cellular products that modify immune activity to treat cancer, autoimmune disorders and selected inflammatory conditions. The revenue boundary includes marketed checkpoint inhibitors, other therapeutic immunomodulatory antibodies, engineered immune-cell products, cytokine-pathway medicines and therapeutic vaccines. It excludes routine chemotherapy, standalone molecular diagnostic testing, contract research fees and unrelated antibody medicines without a demonstrated immune-modulating therapeutic mechanism. Combination regimens count only the revenue attributable to the immunotherapy components, preventing chemotherapy or targeted-drug sales from being added twice.

The International Agency for Research on Cancer estimated 20.6 million new cancer diagnoses and 9.8 million cancer deaths worldwide in 2024. Lung cancer contributed 2.6 million new diagnoses, making it an important source of demand for PD-1 and PD-L1 medicines. The FDA has widened the eligible population through approvals in Hodgkin lymphoma and multiple myeloma, while regulators in China and Japan have authorized new checkpoint combinations. Expanding biomarker testing helps identify patients likely to benefit, although treatment selection remains dependent on tumor type, disease stage and safety.

Bristol Myers Squibb and Merck sell established biologic franchises across oncology indications. Bristol Myers Squibb reported USD 10.0 billion in 2025 Opdivo revenue, alongside USD 2.9 billion for Yervoy and USD 1.4 billion for Breyanzi. Gilead recorded USD 1.8 billion of full-year cell-therapy sales, including Yescarta and Tecartus. BeOne Medicines reported USD 737 million of global Tevimbra revenue, illustrating the contribution from Chinese-origin checkpoint products. Those disclosed sales represent individual products rather than the complete global market, which also includes autoimmune and inflammatory immunomodulators.

A broader treatment mix is changing how immunotherapy is delivered. The FDA approved subcutaneous Keytruda Qlex in September 2025, allowing eligible patients to receive pembrolizumab without a conventional intravenous infusion. Autologous cellular medicines remain dependent on specialist collection, manufacturing and monitoring, while antibody-based regimens can reach outpatient oncology clinics. Across 2026–2034, reimbursement negotiations, biosimilar development, immune-related adverse events and hospital capacity will influence realized revenue per patient as strongly as the pace of new clinical approvals.

Source: IARC 2024 global cancer estimates; BMS 2025 key facts; FDA Keytruda Qlex approval.

Revenue includes marketed immune-modulating medicines and therapeutic cellular products for oncology, autoimmune and inflammatory indications; non-immunotherapy components of combination regimens are excluded.

Drivers Impact Analysis*

Restraints Impact Analysis*

*CAGR contribution shows the percentage points each factor adds to or removes from the 14.2% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.

Cancer incidence and earlier treatment lines increase eligible patients

IARC estimated 20.6 million incident cancer cases worldwide in 2024, with lung cancer alone accounting for 2.6 million. Checkpoint inhibitors are increasingly used before surgery, after surgery and with first-line regimens rather than only after relapse. In March 2026, the FDA cleared nivolumab with AVD chemotherapy for previously untreated advanced classical Hodgkin lymphoma. Earlier treatment extends the population exposed to immunotherapy, although biomarker eligibility and clinical guidelines continue to limit use. For manufacturers, each new indication adds a defined prescriber cohort and a potential longer duration of therapy.

Subcutaneous formulations release hospital infusion capacity

The FDA approved subcutaneous Keytruda Qlex in September 2025 after a trial involving 377 patients with metastatic non-small-cell lung cancer. Response rates were 45% in the subcutaneous arm and 42% with intravenous pembrolizumab in the comparative study. Shorter administration reduces time spent in infusion chairs and may allow outpatient clinics to treat additional patients without proportional facility expansion. Roche and Bristol Myers Squibb are pursuing formulation and lifecycle strategies of their own, making delivery convenience a competitive variable alongside survival outcomes, dosing intervals and contracting terms.

Cellular and bispecific products widen treatment options

The FDA authorized lifileucel in February 2024 for melanoma after prior PD-1 therapy, adding a tumor-infiltrating lymphocyte product to marketed immunotherapy. Regeneron received accelerated approval for the BCMA-directed CD3 bispecific linvoseltamab in July 2025 for heavily pretreated multiple myeloma. These approaches can address patients whose tumors progress despite checkpoint blockade, but require specialized monitoring for severe toxicities. Gilead reported USD 1.8 billion in 2025 cell-therapy sales, demonstrating established commercial demand while also reporting competitive pressure in Yescarta and Tecartus.

Biologic pricing and reimbursement constrain realized growth

NICE recommended nivolumab plus ipilimumab for specified mismatch-repair-deficient colorectal cancers in May 2025 under confidential commercial arrangements. Public funding therefore depends on cost-effectiveness as well as clinical evidence. U.S. drug plans negotiate rebates, and European procurement agencies apply national health-technology assessment and budget limits. High-cost cell therapies also create facility and payer hurdles because hospitals must fund collection, manufacture and post-infusion monitoring. These factors can lower revenue per eligible patient even while treated patient counts rise through 2034.

Immune toxicities and manufacturing complexity limit adoption

Checkpoint inhibitors can trigger pneumonitis, colitis, endocrinopathies and other immune-mediated reactions requiring prompt specialist management. The FDA Keytruda Qlex label retains warnings for immune-related adverse reactions despite its new route. Cell therapies carry additional concerns including severe cytopenia, infection and cardiopulmonary impairment; lifileucel labeling includes a boxed warning. These risks constrain use in frail patients and require trained centers, while autologous production slots and variable turnaround times restrict throughput. Safety surveillance and manufacturing quality investments are necessary costs for sustained market expansion.

Sources: IARC; U.S. FDA; NICE; Bristol Myers Squibb; Gilead Sciences.

Checkpoint combinations enter biomarker-selected earlier lines

In May 2025, NICE supported nivolumab plus ipilimumab for untreated metastatic colorectal cancer with deficient mismatch repair or high microsatellite instability. China subsequently authorized sintilimab with ipilimumab for neoadjuvant treatment of a defined colon cancer population in December 2025. These decisions shift immune therapy toward tumors selected by molecular testing and toward treatment before surgery. Uptake depends on reliable pathology services, reimbursement and whether combination toxicity is acceptable. Earlier-line therapy can increase the duration of exposure, but physicians still weigh checkpoint regimens against established chemotherapy and targeted options.

Asia-origin checkpoint products expand international distribution

BeOne Medicines reported USD 737 million in 2025 sales of tislelizumab, marketed as Tevimbra, with growth across multiple regions. Shanghai Henlius shipped its anti-PD-1 serplulimab to India in 2025 following its European authorization for extensive-stage small-cell lung cancer. China also approved the bispecific ivonescimab for EGFR-mutated lung cancer after tyrosine kinase inhibitor treatment. Wider regional competition introduces new pricing and distribution arrangements outside the largest U.S. franchises. Regulatory submissions and manufacturing inspections remain essential before a product can generate local commercial sales.

Tumor-infiltrating lymphocyte therapies create new referral networks

Lifileucel received accelerated FDA approval in February 2024 for previously treated metastatic melanoma, with an objective response rate of 31.5% among 73 evaluable patients at the recommended dose. Its autologous manufacturing process begins with surgical tumor collection and requires a qualified treatment center for subsequent infusion. Referral networks connecting community oncologists to cellular-therapy facilities therefore affect patient access. Manufacturing capacity and post-treatment safety management limit near-term throughput, even as new clinical studies test similar approaches in additional solid tumors.

Subcutaneous checkpoint products change site-of-care economics

Merck received U.S. approval for Keytruda Qlex on September 19, 2025, covering many solid-tumor indications of intravenous pembrolizumab. The pivotal comparison evaluated pharmacokinetic exposure in 377 participants and reported comparable descriptive response rates. Clinics can schedule shorter administration visits, reducing demand for infusion chairs and nursing time. Payers may still negotiate different net prices for intravenous and subcutaneous presentations, while physicians must follow product-specific indications. Formulation changes can preserve branded relationships as biosimilar development increases competitive pressure on established checkpoint medicines.

Cell therapy and bispecific antibodies compete for later-line patients

Gilead reported that 2025 Yescarta sales fell 5% and Tecartus sales declined 15%, reflecting competitive pressure within and beyond cell therapies. In the same period, Regeneron advanced linvoseltamab for relapsed multiple myeloma after several prior therapies. Bispecific antibodies can avoid patient-specific cell manufacturing, although repeated dosing and immune toxicities remain considerations. Hospitals evaluate treatment outcomes, scheduling capacity and total cost of care when choosing between CAR-T, bispecific and antibody regimens. This competition changes the distribution of revenue without eliminating demand for cellular immunotherapy.

Immune-modulating treatment spans antibody blockade, immune-cell redirection, engineered cell infusion and therapies that suppress pathological immune activation. Product selection is indication-specific and guided by biomarkers, prior treatment, patient fitness and regulatory labeling.

PD-1 and PD-L1 inhibitors remove inhibitory signaling that prevents immune cells from recognizing tumors. Their clinical use spans lung, melanoma, bladder and several biomarker-defined cancers, but response is not uniform across patients. CTLA-4 combinations can improve efficacy in selected settings while raising toxicity burden, making guidelines and clinician experience decisive.

Engineered T-cell therapies and tumor-infiltrating lymphocytes require individualized or specialized manufacturing. CAR-T products such as Yescarta and Carvykti are directed toward selected hematologic malignancies, whereas Amtagvi addresses previously treated melanoma. The distinct supply chains justify separating cell therapies from conventional monoclonal antibodies in the revenue model. Patient-specific manufacturing requires scheduling of collection, product release testing and hospital infusion, and each step can delay treatment for patients with progressing disease.

Outside oncology, immune-modulating antibodies address chronic inflammation and autoimmune disease. China authorized an additional ankylosing-spondylitis indication for IL-17A antibody vunakizumab in 2025. These products often rely on repeat dosing, so persistence and public or private reimbursement shape lifetime revenue differently from time-limited cancer regimens. For IL-17A antibody recipients, repeated administration requires infection screening and specialist follow-up in autoimmune clinics.

Immunotherapy market revenue is allocated to five mutually exclusive therapy classes by principal mechanism. Checkpoint inhibitors cover PD-1, PD-L1 and CTLA-4 blockade, whereas other targeted antibodies exclude checkpoint agents and include non-checkpoint immune-modulating biologics. Engineered cell therapies, therapeutic vaccines and cytokine-related medicines complete the class structure without assigning one product to two categories.

Therapeutic vaccines and cytokine-based medicines account for the remaining smaller classes. Their commercial trajectory depends on disease-specific evidence, duration of treatment and regulatory approval rather than the prescription dynamics of established checkpoint products.

Immunotherapy market applications are assigned by the indication generating revenue. Oncology includes solid tumors and hematologic cancers; autoimmune and inflammatory conditions cover chronic immune dysregulation; infectious disease and other immune-mediated uses are separate. Combination regimens remain in their treatment indication even when the accompanying medicines act through different pathways.

Other immune-mediated indications include selected transplantation and rare immune conditions. Products are allocated according to the treatment indication generating their recognized sales, and trial-stage projects are not assigned commercial revenue before a relevant product launch.

Administration route distinguishes intravenous, subcutaneous, oral and local or intratumoral delivery. Engineered cellular infusions are included in the intravenous class, not treated as a separate overlapping route. Route choice affects patient travel, clinic throughput, infusion-chair demand and the ability to shift care to ambulatory settings.

Local and intratumoral administration contributes a smaller route category for treatments delivered directly to the disease site.

Procurement is allocated to the purchasing channel that recognizes the medicine transaction. Hospital and health-system purchasing, specialty pharmacy dispensing, outpatient infusion center procurement and public tender supply are separated to avoid counting the same vial or cellular product twice as it passes through distribution.

Channel mix differs between U.S. private insurance, European statutory funding and emerging-market public tenders.

Regional demand reflects cancer incidence, autoimmune-disease burden, product approval timing, biologic prices and the availability of specialist infusion and cellular-therapy centers. The 2025 regional model is a reconciled revenue allocation rather than a claim that national pharmaceutical sales are directly audited for this combined therapy definition.

Regulatory development during 2024–2026 expanded checkpoint combinations, bispecific antibodies and cellular immunotherapies. Approval decisions apply to defined populations and should not be generalized across unrelated tumor types.

The FDA approved lifileucel under an accelerated pathway in February 2024, based on response outcomes in previously treated melanoma. The agency requires confirmatory evidence for continued approval where accelerated authorization is conditional. The manufacturing and safety requirements for autologous cellular treatment differ substantially from those of a routine outpatient antibody injection.

Regeneron received accelerated approval for linvoseltamab in July 2025 for multiple myeloma after several prior lines of therapy. The medicine redirects T cells toward BCMA-expressing malignant plasma cells and competes with cellular and other bispecific approaches. Clinical labeling and toxicity monitoring remain essential because immune activation can produce serious reactions.

The FDA added nivolumab plus AVD for previously untreated advanced Hodgkin lymphoma in March 2026. Meanwhile, China authorized a checkpoint combination for selected colon cancers in December 2025, and Japan expanded Opdivo plus Yervoy for MSI-high colorectal disease in August 2025. FDA and NMPA decisions expand specific labeled treatment populations, and postmarketing surveillance tracks adverse reactions after broader clinical adoption. Separate trials remain necessary for unapproved cancer stages and biomarker groups, including populations with different prior treatment histories. Regulators require evidence on immune-related toxicity for new combinations even when their components are already marketed.

Competition spans established PD-1 franchises, autoimmune biologics, bispecific T-cell engagers and autologous cell therapies. Company-level pharmaceutical revenue cannot be equated with the immunotherapy market because portfolios also include non-immunotherapy medicines and diagnostics.

Amgen participates through T-cell engager Blincyto, reporting a 28% full-year sales increase in 2025. Novartis remains a participant through immunology and cellular-therapy portfolios, while Sanofi is active in immune-modulating antibodies for chronic inflammatory conditions. Competitive comparisons require indication-level product attribution because an oncology franchise can include targeted therapies and chemotherapy outside the defined immune-modulating boundary.

New indications can extend the commercial life of checkpoint franchises, but biologic competition and national pricing agreements can limit revenue growth per patient. Gilead disclosed declining 2025 Yescarta and Tecartus sales despite an established cell-therapy business, illustrating that newer immune approaches compete for some of the same later-line patients. Companies with manufacturing reliability, differentiated outcomes and payer evidence are better positioned to maintain access across 2026–2034.

• Merck & Co., Inc.
• Bristol Myers Squibb
• F. Hoffmann-La Roche Ltd
• AstraZeneca PLC
• Regeneron Pharmaceuticals, Inc.
• Gilead Sciences, Inc.
• Johnson & Johnson
• Novartis AG
• Amgen Inc.
• BeOne Medicines Ltd
• Innovent Biologics, Inc.
• Shanghai Henlius Biotech, Inc.
• Iovance Biotherapeutics, Inc.
• Sanofi S.A.

The immunotherapy market is projected to expand from USD 142.0 billion in 2026 to USD 410.9 billion in 2034, corresponding to a 14.2% CAGR. Additional treatment lines and broader regional access support volume, while payer negotiations influence realized product revenue.

Oncology should remain the largest application through 2034 because checkpoint inhibitors and immune-cell therapies are used in multiple major tumor types. Earlier-line approvals can expand eligible populations even when the incidence of a particular cancer changes slowly. IARC projects a substantial increase in the global cancer burden by 2050, creating a long-run need for effective systemic treatments and access to biomarker testing.

Cellular and bispecific therapies are expected to capture additional later-line treatment opportunities, but competition among modalities will remain intense. Gilead reported declining Yescarta and Tecartus sales in 2025 while Regeneron obtained approval for Lynozyfic. Hospitals must evaluate clinical outcomes, toxicity, manufacturing time and reimbursement when selecting products for overlapping patient groups.

North America should retain the largest value pool because of U.S. oncology drug spending and specialist infrastructure. Asia-Pacific may contribute faster patient-volume expansion through domestic approvals, manufacturing scale and regional distribution. European market access will remain linked to national health-technology assessments, and Latin American and African access depends on public budgets, clinical training and reliable supply.

Net-price pressure and future biosimilar competition may reduce revenue per treatment in mature checkpoint categories. Subcutaneous administration can change clinic economics but does not eliminate immune-toxicity monitoring or payer review. Manufacturers that establish new indications, credible survival benefits and efficient distribution should capture a larger share of incremental commercial demand, while therapies lacking differentiated evidence face more restrictive formularies.

Coverage follows commercial immune-modulating therapy revenue by treatment class, clinical indication, delivery route, procurement channel and five regions.